glp-1 insulin resistance Agonist Effects on Glucagon Suppression Endogenous Activation of Glucagon-Like Peptide-1

In the STEP 1 trial (published in the New England Journal of Medicine), participants using Wegovy lost an average of 14.9% of their body weight over 68 weeks approximately 35 lbs from a starting weight of 232 lbs

Later, hypoglycemia was added as a marker for late dumping

Recent Updates November 24, 2025: Updated Sheds treatment options to add Zepbound and remove Ozempic and Mounjaro

Due to these reasons, manufacturers are charging higher prices

2 Metformin (MET) is recommended as the first-line treatment for patients with T2DM due to well-established efficacy, safety, low cost, and data demonstrating a reduction in risk of cardiovascular (CV) events